Zydus receives US FDA approval for anti-viral drug oseltamivir
The group has also received the US drug regulator's nod to market anti-bacterial drug, linezolid
 "Zydus receives US FDA approval for anti-viral drug oseltamivir")
premium
Nesher Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals USA, has received final approval from the US Food & Drug Administration (FDA) to market oseltamivir phosphate capsule in strengths of 30 mg, 45 mg and 75 mg. The drug, an anti-viral used in the prevention and treatment of influenza virus infection, will be produced at the Nesher Pharmaceuticals manufacturing facility located in St. Louis (Missouri, USA).
As per IMS December 2016 (MAT), the estimated sales for oseltamivir phosphate capsule is $382 million.
The group has also received the final approval from the USFDA to market linezolid tablet (600 mg). The drug is an anti-bacterial agent used to treat certain serious bacterial infections and will be produced at the group’s formulations manufacturing facility at the pharma SEZ in Ahmedabad.
The group now has nearly 110 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%